Email Alert | RSS    帮助

中国防痨杂志 ›› 2021, Vol. 43 ›› Issue (9): 879-882.doi: 10.3969/j.issn.1000-6621.2021.09.005

• 专家笔谈 • 上一篇    下一篇

耐药肺结核全口服治疗方案研究的现状和展望

周文强, 张爽, 初乃惠()   

  1. 101149 北京市结核病胸部肿瘤研究所/首都医科大学附属北京胸科医院结核一科
  • 收稿日期:2021-08-04 出版日期:2021-09-10 发布日期:2021-09-07
  • 通信作者: 初乃惠 E-mail:dongchu1994@sina.com
  • 基金资助:
    “十三五”重大新药创制国家科技重大专项(2017ZX09304009);“十二五”国家科技重大专项(2015ZX10003001-002)

Current status and prospect of all-oral treatment regimens for drug-resistant pulmonary tuberculosis

ZHOU Wen-qiang, ZHANG Shuang, CHU Nai-hui()   

  1. Department of Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
  • Received:2021-08-04 Online:2021-09-10 Published:2021-09-07
  • Contact: CHU Nai-hui E-mail:dongchu1994@sina.com

摘要:

结核病是严重的公共卫生问题,是全球十大死亡疾病之一。相对于敏感肺结核的高治愈率,耐药肺结核治疗成功率低、死亡率高。近年来,以抗结核新药为核心的全口服治疗方案获得了巨大的成功,克服了二线注射剂不良反应发生率高、患者治疗依从性差等缺点,提高了耐药肺结核的治疗成功率。但如何选用抗结核药物组成安全有效的全口服方案,以及如何开展相关治疗方案的研究是我们需要思考的问题。笔者通过梳理耐药肺结核化学治疗药物、含注射剂方案向全口服方案过渡以及目前国内外正在开展的短程、超短程全口服方案的相关研究及其制定的依据,结合我国国情,做出了相应的评论、提出了相关的思考及启发,以期为临床科研人员更好的认识和开展相关研究提供参考。

关键词: 结核,肺, 抗药性, 投药,口服, 临床方案, 总结性报告(主题)

Abstract:

Tuberculosis is a serious public health problem and one of the top 10 causes of death worldwide. The treatment success rate is high in sensitive tuberculosis, and low in drug-resistant tuberculosis, while the mortality rate of drug-resistant tuberculosis is high. In recent years, the all-oral regimens with new anti-tuberculosis drugs as the core are greatly successful in treatment, overcoming the high incidence of adverse reactions of second-line injections, poor treatment compliance of patients and other shortcomings, and increasing the treatment success rate of drug-resistant tuberculosis. However, how to select anti-tuberculosis drugs for safe and effective oral regimens, and how to carry out researches on treatment program are still problems. In this paper, by reviewing the transition from chemotherapy drugs and injection-containing regimens to all-oral regimens for drug-resistant tuberculosis, as well as relevant studies on short and ultra-short course all-oral regimens at home and abroad and the basis for the formulation, the author made comments and shared thoughts and inspiration in combination with conditions in China, in order to provide reference for clinical researchers to better understand and carry out related researches.

Key words: Tuberculosis,pulmonary, Drug resistance, Administration,oral, Clinical protocols, Consensus development conferences as topic